The alleged Vivo X300 Ultra global version has been certified by the EEC authority. The listing shows the model number V2562 ...

Vivos Therapeutics, Inc. has announced the publication of positive results from a multicenter clinical trial on its Daytime-Nighttime Appliance (DNA) for treating obstructive sleep apnea (OSA) in ...

You win some, you lose some—and that’s certainly true for Vivos Therapeutics, which reported on Monday the FDA’s clearance of one device to treat obstructive sleep apnea alongside the denial of ...

In much the same way that they’re designed to expand wearers’ upper airways, Vivos Therapeutics’ slate of oral appliances have now expanded their FDA indications, too. Collectively known as the ...

Vivos Therapeutics stock leaped after the medical-technology provider garnered FDA clearance for a device to treat sleep apnea. Vivos Therapeutics (VVOS) shares on Monday leaped after the ...

Vivo X300 Ultra tipped with 6.8-inch 2K 120Hz display, Snapdragon 8 Elite Gen 5, 200MP cameras, 7,000mAh battery, and early ...

LITTLETON, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (VVOS), a leading medical device and technology company specializing in the development and commercialization of highly ...

Credit: Vivos Therapeutics. The FDA clearance was based on data from 73 patients with severe OSA. The Food and Drug Administration (FDA) has cleared the Vivos CARE (complete airway repositioning ...

With this unprecedented FDA clearance, Vivos redefines what it means to have a truly non-invasive treatment for all levels of OSA severity, opening new revenue opportunities for Vivos LITTLETON, Colo.

LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the ...

Vivos Therapeutics Inc (NASDAQ:VVOS) announced the results of a recent clinical observational study on the application of Vivos' Preventive Oral Device, dubbed POD, for treating and preventing ...